Branched Monodispersed PEG Synthesis for ADC Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing branched monodispersed polyethylene glycol are hindered by the difficulty in achieving high purity and the complexity of industrial-scale production, particularly due to the presence of impurities with different ethylene glycol chain lengths, which complicates the production of antibody-drug conjugates and increases costs.
Innovation Solution
A method involving the synthesis of branched monodispersed polyethylene glycol with a functional group that forms a covalent bond on a glycerin backbone, using specific functional groups and intermediate compounds, allowing for simple extraction and avoidance of complex purification methods like column chromatography, resulting in a highly pure product suitable for drug modification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce branched monodispersed polyethylene glycol, then production can proceed with standard techniques, but the product purity is low due to impurities with different ethylene glycol chain lengths
Solution Approach 1:
The patent introduces a protecting group at the terminal of the polyethylene glycol chain during the synthesis stage. This preliminary action prevents unwanted side reactions and ensures that only the desired monodispersed product is formed, eliminating the need for complex post-synthesis purification to remove impurities with different chain lengths.
Solution Approach 2:
The patent employs specific reaction conditions including controlled temperature ranges (0-50°C), specific molar ratios of reactants, and controlled addition rates to ensure monodispersity. By precisely controlling these parameters during synthesis, the product achieves high purity without requiring complex purification equipment or processes.
2Manufacturing precision
If complex purification methods like column chromatography are used, then product purity can be improved, but the production process becomes more complex and costly
Solution Approach 1:
The protecting group is introduced during the synthesis stage to prevent side reactions. This preliminary protective measure ensures that the reaction produces only the desired monodispersed product with the specific ethylene glycol chain length, eliminating the need for complex purification methods like column chromatography and simplifying the overall manufacturing process.
Solution Approach 2:
The patent converts the potential harm of side reactions and impurity formation into a benefit by using the protecting group strategy. What would normally be harmful side products are prevented from forming in the first place, turning the synthesis process into a straightforward route to high-purity product without requiring elaborate purification steps.
3Device complexity
If monodispersed polyethylene glycol is used as a linker main chain, then the structure is simple, but the hydrophobic drug is exposed and stability in blood decreases
Solution Approach 1:
The patent uses a branched structure where a shorter monodispersed polyethylene glycol chain is nested within a branched architecture. The branching point creates a three-dimensional structure where the drug is positioned at the center, surrounded by multiple PEG chains that extend outward. This nested arrangement maintains structural simplicity while effectively shielding the hydrophobic drug from the aqueous environment.
Solution Approach 2:
The patent creates a composite structure combining the hydrophobic drug core with hydrophilic PEG chains in a branched configuration. This composite architecture integrates both hydrophobic and hydrophilic components, allowing the hydrophobic drug to be effectively masked by the surrounding hydrophilic PEG chains, thereby improving stability in blood while maintaining linker simplicity.
4Reliability
If multiple drugs are bonded to an antibody to increase medicinal effect, then therapeutic efficacy improves, but aggregation and decreased stability occur due to hydrophobicity
Solution Approach 1:
The patent employs a composite material strategy by attaching multiple hydrophobic drugs to an antibody through a branched PEG linker. The hydrophilic PEG chains form a protective shell around the hydrophobic drugs, creating a composite structure that prevents drug-drug and drug-antibody aggregation. This allows multiple drugs to be bonded to the antibody, enhancing medicinal effect while maintaining antibody stability in the aqueous bloodstream environment.
Data Source
AI summary
A branched monodispersed polyethylene glycol represented by the formula (1):wherein X1 is a functional group that forms a covalent bond upon a reaction with a functional group present in a biofunctional molecule; n is an integer of 4 to 50, which represents number of repeating units of ethylene oxide units; and L1 represents a single bond, —NH—, -L2-(CH2)m1- or -L2-(CH2)m1-L3-(CH2)m2-, L2 represents an ether bond, an amide bond, an urethane bond or a single bond, L3 represents an ether bond, an amide bond or an urethane bond, and m1 and m2 represent each independently an integer of 1 to 5.